MERCK & CO. INC. (MRK)
US58933Y1055 - Common Stock
MERCK & CO. INC.
NYSE:MRK (12/2/2024, 8:04:00 PM)
After market: 100.66 +0.05 (+0.05%)100.61
-1.03 (-1.01%)
Company Profile
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey and currently employs 72,000 full-time employees. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The company is also engaged in developed a novel class of small molecules that target cancer cells lacking expression of a key DNA repair protein called O6-methylguanine methyl transferase.
Company Info
MERCK & CO. INC.
126 East Lincoln Avenue
Rahway NEW JERSEY 07033
P: 19087404000
CEO: Kenneth C. Frazier
Employees: 71000
Website: https://www.merck.com/
MRK News
4 days ago - ChartmillUncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.What's going on in today's session: S&P500 movers
5 days ago - The Motley FoolThe Smartest Dividend Stocks to Buy With $3,000 Right NowThey may not offer the very highest yields, but their dividends are built to last, and even grow.
5 days ago - BloombergAstraZeneca’s Enhertu Wins China Reimbursement Despite ProbeChina approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance, a move that will boost the British drugmaker’s sales in the country in the midst of an ongoing probe that’s ensnared some of its senior executives.
7 days ago - Merck & Co., Inc.Merck to Participate in the Citi 2024 Global Healthcare Conference8 days ago - Merck & Co., Inc.Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim Analysis
8 days ago - ChartmillWhy NYSE:MRK provides a good dividend, while having solid fundamentals.Why the dividend investor may take a look at MERCK & CO. INC. (NYSE:MRK).
MRK Twits
Here you can normally see the latest stock twits on MRK, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
